Navigation Links
Avid Announces Results of AV-1 Molecular Imaging Agent for,Alzheimer's Disease Presented at AD/PD Meeting

-1 is one of a series of novel compounds discovered in the laboratory of Dr. Hank Kung from the University of Pennsylvania and exclusively licensed to Avid for development and commercialization. The results presented represent a collaborative effort between scientists at Austin Health, the University of Melbourne, Neuroscience Victoria, Avid Radiopharmaceuticals, the University of Pennsylvania, and Bayer Schering Pharma.

New treatment methods for slowing or reversing the deposition of insoluble amyloid in the brains of people with Alzheimer's disease are the subject of intensive clinical research by many large pharmaceutical companies as well as the National Institute of Mental Health (NIMH) (www.nimh.nih.gov/studies/1alzhdis.cfm). Amyloid imaging may help in identifying those patients who will benefit from these emerging treatments.

About Avid

Avid Radiopharmaceuticals, Inc. is developing novel diagnostic imaging agents to enable the early diagnosis, treatment selection and therapeutic monitoring of major medical disorders. The company is a pioneer in the development of molecular imaging agents for Alzheimer's disease. Its lead product candidates are being developed to identify amyloid plaques, which are thought to accumulate in the brain for years before the onset of clinical symptoms of the disease. Avid's compounds may enable the earlier diagnosis of Alzheimer's disease and also allow researchers to better evaluate therapeutic drug candidates for the prevention or reversal of amyloid plaque build-up in the brain. Avid's technology can be used with a variety of imaging technologies such as positron emission tomography (PET) and single photon computed tomography (SPECT) and is currently being tested in a number of pilot human studies. In July 2006 Bayer Schering Pharma AG, Germany, a worldwide leader in specialized pharmaceuticals, and Avid announced a collaboration they have formed through which Bayer Schering Pharma has an exclusive option t
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/15/2009)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), ... announced that a group of its home hemodialysis ... a week-long, conventional (non-dialysis) Caribbean cruise with their ... the "2010 Freedom Cruise: We,re Taking Home Dialysis ... 3, 2010 and returns on January 10, 2010. ...
(Date:12/15/2009)... IRVINE, Calif., Dec. 15 Masimo (Nasdaq: ... and Measure-Through Motion and Low Perfusion pulse oximetry, ... Kiani has been awarded the 2009 Frost & ... North American Patient Monitoring market. According to Frost ... of Mr. Kiani,s "unprecedented ability in understanding customer ...
(Date:12/15/2009)... MALVERN, Pa. and WALTHAM, Mass., Dec. 15 /PRNewswire/ ... find that methicillin-resistant Staphylococcus aureus (MRSA) ... infectious disease specialists with regard to their treatment ... activity against MRSA is among the top factors ... skin and skin structure infections. Other key factors ...
Breaking Medicine Technology:Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 3Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 4Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 2Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 3Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 4Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 5Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 6A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 2A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 3Spokane Washington Man Indicted On Civil Rights Charges Related to Threats to Reproductive Health Services Clinic 55460 1California Life Science Business and Economic Development Experts Discuss Californias Bioscience Future 13708 1California Life Science Business and Economic Development Experts Discuss Californias Bioscience Future 13708 2Newer Better Tests for Heart Attacks 55455 1Newer Better Tests for Heart Attacks 55455 2Newer Better Tests for Heart Attacks 55455 3
... Improve Quality of Life for ... Patients Suffering From Chronic Pain, ALBUQUERQUE, New ... improving patient quality of life,announced today that the U.S. Food ... market KFH Energy in the United,States. The patented, high-tech medical ...
... mechanism of action -, CHICAGO, March 31 ... ranolazine significantly (p<0.001),shortened the QT interval of patients with ... is caused by a genetic mutation in the late,sodium ... including,sudden death. Ranolazine also shortened cardiac relaxation time in ...
Other Medicine Technology:Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers 2Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 2Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 3
(Date:12/15/2009)... how will they get paid for patient care? Capture,s medical ... , ... Washington, DC (Vocus) December 15, ... codes. These codes are what healthcare providers submit to ... medical consultation, whether in a provider’s office or hospital setting. ...
(Date:12/15/2009)... America,s premier manufacturer of Spa, Massage, and Medical tables announces ... an adjustable breast comfort system to ease pressure felt while ... ... New Freedom, Pennsylvania (PRWEB) December 15, 2009 -- OAKWORKS®, ... equipment, today announced the launch of the Utopian Massage Table ...
(Date:12/15/2009)... Ill. A study in the Dec. 15 issue ... shows that being overweight or obese increases the risk ... not in younger children. , Results indicate ... years of age and older increased 3.5 fold with ... while the risk of OSA did not significantly increase ...
(Date:12/14/2009)... carry oxygen, drugs, and more… , ... ... Barbara, in collaboration with scientists at University of Michigan, have ... functions of natural red blood cells, including softness, flexibility, and ... ,The primary function of natural red blood cells is to ...
(Date:12/14/2009)... Heska Corporation (Nasdaq: HSKA ... provider of veterinary diagnostic and specialty products, ... the Company,s new DRI-CHEM® 7000 Veterinary Chemistry ... http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ) ,, Customers receiving these analyzers ... chemistry analyzer available to the veterinary in-clinic ...
Breaking Medicine News(10 mins):Health News:Medicare Eliminates Consultation Codes for Doctors 2Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 2Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 3Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 4Health News:Obesity increases the risk for obstructive sleep apnea in adolescents, but not in younger children 2Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3Health News:Heska Announces Installation of New Chemistry Analyzer 2Health News:Heska Announces Installation of New Chemistry Analyzer 3
... 10 According to the American,Diabetes Association there ... States who have diabetes and approximately one million ... 2007, 17.5 million diagnosed,diabetics in the U.S. resulted ... response to this growing epidemic, Health Management Corporation,(HMC), ...
... Oklahoma and Louisiana, MINERAL WELLS, Texas, Nov. ... and bottled by Famous Mineral Water Co. in ... Foods Market,locations across Texas, Oklahoma and Louisiana. This ... of the only domestically bottled mineral,water available in ...
... HI ) will announce its fourth-quarter earnings results ... text of the release and,financials will be available on ... company will hold a conference call and simultaneous webcast ... ET. The webcast is,available through the Investor Relations section ...
... But researchers are working on new therapies to combat the ... of U.S. children allergic to foods such as peanuts, milk ... researchers are working on new approaches to treating these allergies, ... American College of Allergy, Asthma and Immunology,s annual meeting, in ...
... Initial Physician Experience with Eculizumab in Patients ... Presented, CHESHIRE, Conn., Nov. 10 ... announced that the American,Society of Hematology (ASH) ... as a treatment for patients with paroxysmal,nocturnal ...
... 10 TransTech Services Partners,Inc. (OTC Bulletin Board: ... Dr. Ranga C. Krishna as a director at ... licensed neurologist and an experienced,health care entrepreneur, having ... Inc., a company which assists U.S.,pharmaceutical companies perform ...
Other Medicine News:Health News:Health Management Corporation Incorporates Clinically Proven Care Diabetes Management Program With Programming From dLife 2Health News:Health Management Corporation Incorporates Clinically Proven Care Diabetes Management Program With Programming From dLife 3Health News:Crazy Water Expands Distribution to Whole Foods Market(R) 2Health News:Crazy Water Expands Distribution to Whole Foods Market(R) 3Health News:Childhood Food Allergies on the Rise 2Health News:Childhood Food Allergies on the Rise 3Health News:Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting 2Health News:Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting 3Health News:Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting 4
DNA/RNA preparation in 384-well format...
... refrigerator -4C. 5.2 Cubic ... Interior light. Manual push ... drawers. Two shelves. In-door ... Adjustable thermostat. Magnetic gasket. ...
... Alternative to Bottled Water, The Simplicity personal ... laboratories that currently use bottled water. In ... ship and store bottled water, your laboratory ... contamination can be absorbed from containers and ...
... Produces up to 12 L/min of Type ... On Demand, The Super-Q Plus System is ... water which has been pretreated by reverse ... consistently produce ultrapure water quality which exceeds ...
Medicine Products: